close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

41.17 -0.08 (-0.19%)
Delayed Quote Updated: 3:01 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
35 36 Next >
News headline image
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Engages In Settlement Talks Over Medicare Kickback Allegations ↗
Teva Pharmaceutical is negotiating with the DOJ to settle a lawsuit alleging it paid kickbacks through charities to boost Copaxone sales, risking up to $10 billion in damages. 
Via Benzinga
Topics Lawsuit
News headline image
Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know ↗
Corcept Therapeutics Inc. (NASDAQ: CORT) shares are trading lower Friday afternoon following a report suggesting Teva Pharmaceuticals Inc. (NYSE: TEVA) has sued the company, accusing it of a monopoly... 
Via Benzinga
Topics Lawsuit
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today ↗
 
Via Benzinga
News headline image
4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know ↗
 
Via Benzinga
News headline image
Teva Pharmaceutical Indus's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
7 A-Rated Biotech Stocks Worth Betting on in June ↗
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace
News headline image
What is a Bull Flag Pattern? Explanation and Examples
Learn how to identify and trade the bull flag pattern, which is a key tool for spotting continuations in bullish trends. 
Via MarketBeat
News headline image
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
2 Generic Drug Makers With Growing Runways
Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out. 
Via MarketBeat
Topics Intellectual Property
News headline image
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Alvotech
Via GlobeNewswire
News headline image
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch ↗
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). 
Via Benzinga
Topics Cannabis
News headline image
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade ↗
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
News headline image
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
These 10 Large Cap Stocks Shined Brightest Last Week (May 5-May 11, 2024): Are They In Your Portfolio? ↗
Toast, Teva, Vistra, Equinix, Applovin, IFF, Constellation, Emerson, IP, and STERIS were top performers last week. Are they in your portfolio? 
Via Benzinga
News headline image
These 7 Stocks Surged Double-Digits and Have Double-Digits to Go
Stocks surging on earnings reports often continue moving higher over time. This is a look at seven that surged more than 10% on Q1 results. 
Via MarketBeat
News headline image
Teva Pharmaceutical Industries (TEVA) Q1 2024 Earnings Call Transcript ↗
TEVA earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higher ↗
Results from the Phase 3 SOLARIS trial of TEV-‘749 for schizophrenia treatment. SteadyTeq technology ensures controlled olanzapine release. Clinically meaningful improvements in PANSS scores observed... 
Via Benzinga
News headline image
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
TEVA Stock Earnings: Teva Pharmaceutical Indus Misses EPS, Beats Revenue for Q1 2024 ↗
TEVA stock results show that Teva Pharmaceutical Indus missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Teva Surges To 5-Year High On Maintained Outlook Despite Mixed First Quarter ↗
The company missed first-quarter earnings forecasts by 4 cents a share, but sales beat. 
Via Investor's Business Daily
News headline image
Wall Street Poised For Muted Open On Mixed Earnings, With More Fed Speeches In Store: Analyst Sees S&P 500 Crossing Late-March High ↗
U.S. stocks are on track for a mixed start on Wednesday as the market digests mixed earnings reports and looks ahead to more speeches by Federal Reserve officials. 
Via Benzinga
Topics Economy Stocks
News headline image
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.